Growth Hormone Secretion Peptides: Mechanisms, Signaling and Current Research

Research into the Growth Hormone Secretion Peptide class examines how peptide-based compounds interact with the hypothalamic-pituitary growth hormone axis. Rather than supplying growth hormone directly, these compounds are generally studied for their ability to influence endogenous signalling pathways that regulate pulsatile GH release.

Growth hormone secretion is controlled by a balance between stimulatory signals such as growth hormone-releasing hormone (GHRH) and ghrelin-related signalling, and inhibitory signals such as somatostatin. Feedback from circulating GH and insulin-like growth factor 1 (IGF-1), together with sleep, nutrition, age, sex, and metabolic state, further shapes the secretory pattern. (Growth Hormone: Synthesis and Regulation, 2026)

Compounds such as Ipamorelin, GHRP-6, Sermorelin, and CJC-1295-related GHRH analogues are therefore useful research tools for examining different points within this regulatory network. However, their mechanisms, molecular targets, and evidence bases are not identical.

For researchers looking for peptide materials for laboratory investigation, visit the Nume Peptides to explore the available research peptide collection.

How Is Growth Hormone Secretion Regulated?

Growth hormone is produced by somatotroph cells in the anterior pituitary. Its secretion is pulsatile rather than constant, with hormone concentrations rising and falling throughout the day.

The hypothalamus provides two major regulatory signals. GHRH stimulates GH synthesis and release, whereas somatostatin suppresses secretion. Ghrelin and synthetic growth hormone secretagogues can provide an additional stimulatory pathway through the growth hormone secretagogue receptor.

Recent neuroendocrine research continues to describe GH secretion as the result of coordinated excitatory and inhibitory signalling rather than a simple on/off mechanism. (Montero-Hidalgo et al., 2025)

Several physiological factors can influence this system:

• sleep and circadian timing;
• nutritional status;
• fasting;
• age;
• sex;
• exercise;
• metabolic signals;
• circulating GH and IGF-1.

Negative feedback within the GH–IGF-1 axis

Growth hormone stimulates IGF-1 production in several tissues, particularly the liver. GH and IGF-1 then participate in feedback mechanisms that influence subsequent GH secretion.

Human studies have demonstrated that changes in circulating IGF-1 can alter responsiveness of the GH axis, illustrating why secretagogue responses may vary with metabolic state. (Fasting and GH Secretagogue Study, 2001)

Explore research compounds studied for GH secretion, GHRH signaling, and secretagogue pathways in the Growth Hormone collection.

Which Biological Pathways Control Growth Hormone Release?

Different peptide secretagogues can stimulate GH through different receptor systems.

GHRH receptor signalling

GHRH binds to the GHRH receptor on pituitary somatotrophs. This activates intracellular signalling that promotes both GH synthesis and release.

The biologically active N-terminal region of GHRH is particularly important. Research on GHRH fragments demonstrated that shortened GHRH(1-29) peptides retain substantial GH-releasing activity, which provided the foundation for analogues such as Sermorelin. (Grossman et al., 1984)

Growth hormone secretagogue receptor signalling

GHRP compounds and ghrelin-related secretagogues act through the growth hormone secretagogue receptor, commonly designated GHS-R1a.

This pathway is mechanistically distinct from the GHRH receptor pathway, although the two systems interact strongly.

Human experiments with GHRP-6 demonstrated that blocking endogenous GHRH markedly reduced the GH response to GHRP-6. This indicates that normal hypothalamic GHRH signalling contributes substantially to the full secretagogue response. (Mallo et al., 1998)

Why combined pathway research is important

Experimental studies have repeatedly found that GHRH and GHRP signalling can produce greater GH responses when studied together than when examined separately.

This makes the GH axis particularly useful for studying interactions between:

1. hypothalamic signalling;
2. pituitary receptor activation;
3. somatostatin tone;
4. ghrelin-related pathways;
5. GH and IGF-1 feedback.

Researchers should therefore avoid treating every Growth Hormone Secretion Peptide as acting through the same receptor.

How Are Peptides Studied in Growth Hormone Secretion Research?

Growth hormone secretagogues have been investigated using cell-based assays, animal models, endocrine challenge tests, pharmacokinetic studies, and human clinical research.

Pituitary cell models

Cultured pituitary cells allow researchers to determine whether a peptide directly stimulates GH release and which receptor pathways are involved.

Common endpoints include:

• GH concentration;
• dose-response relationships;
• receptor antagonism;
• intracellular signalling;
• selectivity relative to other pituitary hormones.

These systems are particularly useful for separating GHRH-receptor activity from GHS-R-related activity.

Animal research

Animal studies can provide information about receptor selectivity, endocrine responses, pharmacokinetics, and secondary hormone effects.

For example, early Ipamorelin research compared GH, ACTH, cortisol, and other pituitary responses in experimental systems. (Raun et al., 1998)

Human endocrine studies

Human studies often measure:

• baseline GH;
• peak GH response;
• GH area under the curve;
• IGF-1;
• timing of GH pulses;
• pharmacokinetic parameters.

These studies provide stronger translational evidence than cell or animal models, but results still depend on age, metabolic state, endocrine function, and study population.

Which Peptides Are Investigated for Growth Hormone Secretion?

The four compounds considered here fall into two broad mechanistic groups: GHS-R-related secretagogues and GHRH-related peptides.

Ipamorelin

Ipamorelin is a synthetic pentapeptide developed as a selective growth hormone secretagogue.

Preclinical research found that it stimulated GH release through a GHRP-like receptor pathway. Compared with GHRP-6 and GHRP-2 in the experimental models used, Ipamorelin showed greater selectivity for GH without producing comparable increases in ACTH or cortisol. (Raun et al., 1998)

Human pharmacokinetic and pharmacodynamic research subsequently demonstrated episodic GH release after Ipamorelin exposure and characterized the relationship between peptide concentrations and GH responses. (Gobburu et al., 1999)

GHRP-6

GHRP-6 is a synthetic hexapeptide and one of the best-characterized early GH secretagogues.

Human studies demonstrated that GHRP-6 can stimulate substantial GH release and that the response interacts strongly with endogenous GHRH signalling. (Mallo et al., 1998)

Research comparing GHRP-6 and GHRH has also shown that combined stimulation can produce larger GH responses than either compound alone. (Peñalva et al., 1993)

Unlike Ipamorelin, GHRP-6 research has also documented effects involving ACTH and cortisol under certain experimental conditions, demonstrating that secretagogues within the same broad class can have different endocrine profiles.

Sermorelin

Sermorelin corresponds to an amidated GHRH(1-29) fragment and acts through the GHRH receptor pathway rather than the ghrelin/GHS-R pathway.

Human studies found that GHRH(1-29) can stimulate pituitary GH release with activity comparable to longer endogenous GHRH fragments under experimental conditions. (Grossman et al., 1984)

Research therefore uses Sermorelin-like GHRH fragments to investigate pituitary GH reserve and GHRH receptor responsiveness.

CJC-1295 (No DAC)

Terminology around “CJC-1295 (No DAC)” requires particular caution.

Published human research on CJC-1295 primarily describes a long-acting GHRH analogue incorporating a Drug Affinity Complex, or DAC. In healthy adults, this long-acting CJC-1295 produced sustained increases in GH and IGF-1 lasting several days. (Teichman et al., 2006)

The commercial term “CJC-1295 No DAC” is commonly used for a shorter-acting modified GHRH(1-29)-type peptide. Therefore, findings from the long-acting DAC-linked CJC-1295 study should not automatically be attributed to a No-DAC material.

Research on modified GHRH(1-29) analogues shows that amino-acid substitutions can substantially alter stability and GH-releasing potency. (Rivier et al., 1988)

For research reproducibility, sequence, molecular mass, HPLC purity, batch documentation, and exact peptide nomenclature are especially important when comparing GHRH analogues.

Discover research peptides with ≥99% HPLC-verified purity and batch-specific COA documentation – Ipamorelin (10 mg).

What Does Current Research Show About Peptide-Mediated Growth Hormone Secretion?

Current evidence clearly shows that multiple peptide systems can experimentally stimulate GH release. However, the amount and type of evidence differ between compounds.

Ipamorelin has both preclinical and human pharmacokinetic research demonstrating GH secretagogue activity. GHRP-6has substantial human endocrine research showing stimulation of GH and strong interaction with endogenous GHRH.

Sermorelin is supported by earlier human research on GHRH(1-29), while CJC-1295 research requires careful distinction between long-acting DAC-containing material and shorter GHRH analogues sold under No-DAC terminology.

Researchers should evaluate several levels of evidence:

• receptor activation;
• pituitary GH release;
• circulating GH concentrations;
• changes in IGF-1;
• duration of endocrine response;
• effects on additional pituitary hormones.

An increase in circulating GH is an endocrine measurement. It should not automatically be interpreted as evidence of muscle gain, recovery, anti-aging effects, or another downstream clinical outcome.

Canadian research context

Health Canada has seized unauthorized injectable products labelled as CJC-1295, GHRP-6, Ipamorelin, and Sermorelin in Canada. Health Canada states that unauthorized products have not been assessed for therapeutic safety, efficacy, or quality. (Health Canada, 2025)

This regulatory context should remain separate from laboratory research. Evidence that a peptide stimulates GH experimentally does not establish authorization for therapeutic use in Canada.

Explore research peptides with ≥99% HPLC-verified purity and batch-specific COA documentation – CJC-1295 (No DAC) (10 mg).

FAQs About Growth Hormone Secretion Peptides

What Is a Growth Hormone Secretion Peptide?

It is a peptide investigated for its ability to stimulate endogenous growth hormone release through pathways such as GHRH receptor signalling or the growth hormone secretagogue receptor.

Do All GH Secretagogues Use the Same Receptor?

No. Sermorelin and GHRH-related peptides primarily target the GHRH receptor, while Ipamorelin and GHRP-6 act through GHS-R-related pathways.

How Does Ipamorelin Differ From GHRP-6?

Both are growth hormone secretagogues, but early experimental studies found Ipamorelin to have greater selectivity for GH release, whereas GHRP-6 could also influence ACTH and cortisol responses. (Raun et al., 1998)

What Is Sermorelin?

Sermorelin is an amidated GHRH(1-29) peptide that stimulates GH release through the pituitary GHRH receptor pathway.

Is CJC-1295 (No DAC) the Same as CJC-1295 With DAC?

No. Researchers should distinguish the shorter-acting No-DAC terminology from the long-acting DAC-linked CJC-1295 studied in published human trials.

Does Increased GH Automatically Mean Increased IGF-1?

Not necessarily. GH and IGF-1 are connected within the somatotropic axis, but the magnitude and duration of IGF-1 responses depend on multiple physiological and experimental factors.

Conclusion

Research into the Growth Hormone Secretion Peptide class demonstrates that endogenous GH release can be influenced through more than one biological pathway.

Ipamorelin and GHRP-6 primarily represent growth hormone secretagogue receptor-related research, while Sermorelin and CJC-1295-related compounds belong to the GHRH analogue side of the GH axis. Their receptor targets, endocrine selectivity, pharmacokinetics, and supporting evidence should therefore be evaluated separately.

Researchers should also distinguish pituitary GH secretion from downstream IGF-1 responses and both from broader physiological or clinical outcomes. An experimentally measured rise in GH does not independently establish another claimed biological effect.

For researchers looking for peptide materials for laboratory investigation, visit the Nume Peptides to explore the available research peptide collection.

Disclaimer: This content is provided for educational and scientific research purposes only. Research peptides are intended for laboratory research only and are not intended for human consumption or medical use.